Monday, October 12, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 13, 2026

CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP

View original at seekingalpha.com
CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP Earnings Call Insights: CareTrust REIT (CTRE) Q4 2025 MANAGEMENT VIEW * David Sedgwick, CEO, described 2025 as a “transformational year” for CareTrust, highlighting a record pace of investments and the company’s expansion into the U.K…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SHOP deals are heavily marketed and the company targets a low double-digit IRR

    80% confidence

  • Q4 investments totaled approximately $562 million with a blended stabilized yield of 8.8%

    80% confidence

  • Most competition is seen in SHOP where cap rates continue to compress as investors seek more exposure

    80% confidence

  • CareTrust doubled its team of professionals in 2025 and brought in-house capabilities like tax and data science

    80% confidence

  • The start of 2026 feels very much like deja vu all over again compared to the beginning of 2025

    80% confidence

  • 2025 was a transformational year for CareTrust with record pace of investments and expansion into U.K. care home market and U.S. SHOP

    80% confidence

  • With great operators and beefy coverage, CareTrust can manage through any headwinds in skilled nursing

    80% confidence

  • Q4 normalized FFO increased 42.7% year-over-year to $104.1 million and normalized FAD increased 38.7% to $103 million

    80% confidence

  • Investment pipeline remains strong at approximately $500 million

    80% confidence

  • Data analytics team is prioritized on building out SHOP capabilities but will ultimately impact the whole organization

    80% confidence

  • 2026 guidance does not assume any new investments, dispositions, debt repayments, or equity issuances beyond those announced to date

    80% confidence

  • The difference for continued strong growth is that the team is deeper and more capable, and they have the U.K. and SHOP TAMs to play in as well

    80% confidence

  • The $500 million pipeline is about half U.K. care homes, about one-third U.S. skilled nursing, and the rest is a combination of SHOP deal, triple-net seniors and a couple of small loans

    80% confidence

  • The skilled nursing environment is in a really good place right now with labor in a much better place than recent history

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,371 source documents archived
Query this data → isubstrate.com
CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP — Source | Via News | Via News